<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824248</url>
  </required_header>
  <id_info>
    <org_study_id>B.U.N. 1432021000411</org_study_id>
    <nct_id>NCT04824248</nct_id>
  </id_info>
  <brief_title>Weight Reduction in CLBP</brief_title>
  <official_title>The Added Value of a Behavioral Weight Reduction Program to Blended Rehabilitation in Patients With Chronic Low Back Pain: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will recruit overweight/ obese participants between the age of 18 and 65 with chronic&#xD;
      nonspecific low back pain . The participants will be randomly assigned to one of two&#xD;
      interventions (each lasting 10 weeks). All interventions will be delivered online and will be&#xD;
      a combination of online education material and face-to-face video calls with a physical&#xD;
      therapist. The first group (experimental intervention) will receive a behavioral weight&#xD;
      reduction program combined with pain neuroscience education plus cognition-targeted exercise&#xD;
      therapy. Participants in the second group (control intervention) will receive pain&#xD;
      neuroscience education and cognition-targeted exercise therapy alone. Allocation to the&#xD;
      groups will be at random. Participants and assessors will be blinded for group allocation.&#xD;
      The primary outcomes is pain intensity. Secondary outcomes include other pain related&#xD;
      outcomes, body composition, physical activity, sedentary behavior, dietary intake and&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled clinical trial, including two comparative, balanced online treatment arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>Change from baseline to 6 months (T3) after therapy completion</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>Difference between groups at 6 months (T3) after therapy completion</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>Baseline assessment (T0)</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>T1 assessment directly post treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain inventory (BPI)</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Questionnaire for assessing clinical pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization inventory (CSI)</measure>
    <time_frame>Baseline Assessment (T0)</time_frame>
    <description>Questionnaire to asses self-reported signs of central sensitization and its overlapping symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization inventory (CSI)</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Questionnaire to asses self-reported signs of central sensitization and its overlapping symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization inventory (CSI)</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Questionnaire to asses self-reported signs of central sensitization and its overlapping symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization inventory (CSI)</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Questionnaire to asses self-reported signs of central sensitization and its overlapping symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA Bio-electrical Impedance Analyzer</measure>
    <time_frame>Baseline assessment (T0)</time_frame>
    <description>Body weight measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA Bio-electrical Impedance Analyzer</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Body weight measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA Bio-electrical Impedance Analyzer</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Body weight measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECA wall-fixed SECA wall-fixed stadiometer</measure>
    <time_frame>Baseline measurement</time_frame>
    <description>Body height measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECA wall-fixed SECA wall-fixed stadiometer</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Body height measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECA wall-fixed SECA wall-fixed stadiometer</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Body height measurement used to calculate BMI (= weight[kg] / height[m]²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - body fat</measure>
    <time_frame>Baseline</time_frame>
    <description>Body composition measurement - body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - body fat</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Body composition measurement - body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - body fat</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Body composition measurement - body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - fat free mass</measure>
    <time_frame>Baseline</time_frame>
    <description>Body composition measurement - fat free mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - fat free mass</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Body composition measurement - fat free mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - fat free mass</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Body composition measurement - fat free mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - hydration status</measure>
    <time_frame>Baseline</time_frame>
    <description>Body composition measurement - hydration status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - hydration status</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Body composition measurement - hydration status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TANITA MC-780SMA Bio-electrical Impedance Analyzer - hydration status</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Body composition measurement - hydration status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Frequency Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Self report questionnaire to asses dietary intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Frequency Questionnaire</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Self report questionnaire to asses dietary intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Frequency Questionnaire</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses dietary intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Frequency Questionnaire</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses dietary intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>Baseline</time_frame>
    <description>Self report questionnaire to asses physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Self report questionnaire to asses physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedentary Behavior Questionnaire of Busschaert et a</measure>
    <time_frame>Baseline</time_frame>
    <description>Self report questionnaire to asses sedentary behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedentary Behavior Questionnaire of Busschaert et a</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Self report questionnaire to asses sedentary behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedentary Behavior Questionnaire of Busschaert et a</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses sedentary behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedentary Behavior Questionnaire of Busschaert et a</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Self report questionnaire to asses sedentary behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Short Form Health Survey-36 items (SF-36)</measure>
    <time_frame>Baseline</time_frame>
    <description>Self report questionnaire to evaluate functional status and well-being or quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Short Form Health Survey-36 items (SF-36)</measure>
    <time_frame>T1-assessment directly post-treatment (i.e. 10 weeks after baseline)</time_frame>
    <description>Self report questionnaire to evaluate functional status and well-being or quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Short Form Health Survey-36 items (SF-36)</measure>
    <time_frame>T2-assessment 3 months after therapy completion</time_frame>
    <description>Self report questionnaire to evaluate functional status and well-being or quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Short Form Health Survey-36 items (SF-36)</measure>
    <time_frame>T3-assessment 6 months after therapy completion</time_frame>
    <description>Self report questionnaire to evaluate functional status and well-being or quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Low-back Pain</condition>
  <condition>Overweight or Obesity</condition>
  <arm_group>
    <arm_group_label>Experimental intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pain Neuroscience Education</intervention_name>
    <description>Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.</description>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_label>Experimental intervention</arm_group_label>
    <other_name>Pain Education</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognition-targeted exercise therapy</intervention_name>
    <description>Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.</description>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_label>Experimental intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral weight reduction program</intervention_name>
    <description>Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.</description>
    <arm_group_label>Experimental intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight (BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) with chronic low back pain&#xD;
&#xD;
          -  Non-specific low back pain for at least 3 months' duration&#xD;
&#xD;
          -  Currently seeking care for low back pain&#xD;
&#xD;
          -  Native Dutch speaker&#xD;
&#xD;
          -  Access to internet and computer/tablet/smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leg pain of 7 or higher (on a maximum of 10) on a numeric rating scale&#xD;
&#xD;
          -  Evidence of specific spinal pathology (e.g., hernia, spinal stenosis,&#xD;
             spondylolisthesis, infection, spinal fracture or malignancy)&#xD;
&#xD;
          -  Evidence of a severe underlying comorbidity (e.g. diabetes, cardiovascular problems,&#xD;
             metabolic diseases)&#xD;
&#xD;
          -  BMI ≥ 40 kg/m2&#xD;
&#xD;
          -  Being pregnant or given birth in the preceding year&#xD;
&#xD;
          -  Currently receiving dietary or exercise interventions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anneleen Malfliet, PhD</last_name>
    <phone>003224774503</phone>
    <email>anneleen.malfliet@vub.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneleen Malfliet, PhD</last_name>
      <email>anneleen.malfliet@vub.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Malfliet Anneleen</investigator_full_name>
    <investigator_title>Prof. Dr. Anneleen Malfiet</investigator_title>
  </responsible_party>
  <keyword>chronic low back pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>physiotherapy</keyword>
  <keyword>physical therapy</keyword>
  <keyword>weight reduction</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

